KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

KemPharm, a specialty pharmaceutical company, announced that Travis C. Mickle, Ph.D., will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available starting at 9:00 a.m. ET on September 13. Registered attendees can access the presentation through the conference's virtual platform.

KemPharm focuses on developing prodrugs for serious medical conditions using its proprietary LAT® technology. The company’s pipeline includes treatments for ADHD and CNS rare diseases.

CELEBRATION, Fla., Sept. 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will present virtually at the H.C. Wainwright 23^rd Annual Global Investment Conference taking place September 13-15, 2021. The prerecorded presentation will be available starting at 9:00 a.m., ET on September 13, 2021, and can be accessed via the conference’s virtual platform by registered conference attendees.

Details of the presentation are as follows:

Event:	H.C. Wainwright 23rd Annual Global Investment Conference
Date:	September 13-15, 2021
Time:	Presentations available starting at 9:00 a.m., ET on September 13, 2021
Registration:	https://hcwevents.com/annualconference/

About KemPharm:

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT^® (Ligand Activated Therapy) technology.  KemPharm utilizes its proprietary LAT^® technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm’s prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, stimulant use disorder (SUD) and CNS rare diseases, including idiopathic hypersomnia (IH). KemPharm’s lead clinical development candidate for the treatment of SUD, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate (SDX). In addition, KemPharm has received FDA approval for AZSTARYS^TM, a new once-daily treatment for ADHD in patents age six years and older, and for APADAZ^®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook and YouTube.

KemPharm Contacts:

Tiberend Strategic Advisors, Inc.
Jason Rando/Maureen McEnroe, CFA
(212) 375-2665 / 2664
jrando@tiberend.com
mmcenroe@tiberend.com

FAQ

What is the date of KemPharm's presentation at the H.C. Wainwright conference?

KemPharm's presentation will occur from September 13-15, 2021.

What time will KemPharm's presentation be available?

The presentation will be available starting at 9:00 a.m. ET on September 13, 2021.

Where can I register for the H.C. Wainwright conference?

You can register for the conference at https://hcwevents.com/annualconference/.

What technology does KemPharm utilize for its drug development?

KemPharm utilizes its proprietary LAT® (Ligand Activated Therapy) technology to develop prodrugs.

What medical conditions does KemPharm's pipeline address?

KemPharm's pipeline focuses on ADHD, stimulant use disorder, and CNS rare diseases.